Skip to main content
. 2019 Jan 3;21:101095. doi: 10.1016/j.redox.2018.101095

Fig. 3.

Fig. 3

HSP22 reduces diabetes-induced endothelial injuryin vivo. Diabetes was induced in wild-type (WT) and transgenic (TG) mice by HFD adjuvanted with STZ injection for 12 weeks (n = 8 per group). A) Blood glucose concentrations in the WT-control, TG-control, WT-diabetic and TG-diabetic mice were measured at baseline and 4, 8, and 12 weeks after diabetes induction. B) The body weights of the WT-control, TG-control, WT-diabetes and TG-diabetes mice were measured at baseline and 4, 8, and 12 weeks after diabetes induction. C) Representative images of H&E staining (original magnification ×40). D) Representative immunohistochemical staining images of HSP22, ICAM-1 and VCAM-1 in aortic sections (original magnification ×40). E) Quantification of positive staining for HSP22 in aortic sections. n = 5. F) mRNA expression of HSP22 in the aorta. G) Quantification of positive staining for ICAM-1 and VCAM-1 in aortic rings. n = 5. H) mRNA expression of IL5, IL6, IL13, Mip3α and TGFβ1 in the aorta. *P < 0.05 vs. WT-control; #P < 0.05 vs. WT-diabetes；&P < 0.05 vs. TG-control.